Protara Therapeutics announces presentation of results from THRIVE-1 study
Protara Therapeutics (TARA) announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline ...
Hosted on MSN1y
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
The company expects to start a registrational trial to support FDA approval of IV Choline Chloride for PN patients in the first half of 2025.
Nasdaq17d
Protara Therapeutics To Present THRIVE-1 Study Results On Choline Deficiency At ASPEN 2025
(RTTNews) - Protara Therapeutics, Inc. (TARA), Wednesday announced that data from its THRIVE-1 study will be presented at the American Society for Parenteral and Enteral Nutrition or ASPEN 2025 ...